Marc Miravitlles Spain

Marc Miravitlles, MD, FERS, is a senior researcher and a consultant in the Pneumology Department at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute in Barcelona, Spain. He has served as chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and guidelines director of the ERS. He has also acted as a consultant for the development of international guidelines of chronic obstructive pulmonary disease (COPD), including the American Thoracic Society (ATS)/ERS guidelines on exacerbations of COPD and the ERS statement on the management of respiratory disease in alpha-1 antitrypsin deficiency. He is currently a consultant to the Spanish Ministry of Health for the development of the National Strategy Against COPD and the president of the ERS (2026-2027). In addition, he has served as the coordinator of the Spanish National Guidelines for COPD since 2011. Dr Miravitlles is the author or coauthor of more than 650 peer-reviewed publications in the fields of COPD and alpha-1 antitrypsin deficiency.
Job Title
President
Faculty / Department / Division
Respirology
Institution / Organisation
European Respiratory Society

20 November 2026, Friday

Time Session
14:00
15:00
Ernest Mau Ern Poh Chairperson Malaysia
Lalitha Pereirasamy Chairperson Malaysia
  • Michelle Gong Speaker United States
    Respiratory medicine's evidence base is skewed by Asia's near-absence from clinical trials, and that this is not merely an equity problem but a scientific one — Asia holds close to 60% of the world's population and therefore the largest absolute number of pneumonia deaths, yet the diversity within the continent is treated as a single category. The diversity extends to management and inflammatory profiles in ARDS. This has implications with personalized care and trials. Precision therapy already shows access disparities in Asia mirroring those documented for molecular testing in lung cancer elsewhere. Chronic disease phenotypes diverge as well — COPD risk centers more on biomass fuel and prior TB exposure than smoking; lung cancer shows higher rates of non-smoking adenocarcinoma and EGFR mutation; bronchiectasis trends toward post-TB incidence and a dry phenotype with lower bacterial burden; asthma sub-phenotypes vary country to country. But this diversity in Asia are also opportunities for research. This can be done by leveraging existing data sources and collecting new registry data (retrospective or prospective) to establish disease burden. One can start locally and then link data across sites. Collaborate for team science, and participate in pragmatic comparative-effectiveness and implementation trials that embed into routine care without placebo or drug preparation are also opportunities. Given limited resources, researchers should choose questions no one has answered locally and collect only the key data that can be done routinely during clinical practice. Professional meetings are an important route to multi-country teams and research. One key element is the need to invest in training physicians in research methods so that they can lead research in their own country. ATS MECOR (Methods in Epidemiologic, Clinical and Operations Research) is one model for building that capacity.
  • Shigeo Muro Speaker Japan
    Respiratory medicine increasingly relies on evidence generated across different populations. Yet clinical findings from one region may not fully describe patients in another. Asia is highly diverse, and differences may exist both between Asian and Western patient groups and among populations within Asia. As an example of diversity within Asia, the frequency of EGFR mutations in lung adenocarcinoma varies across Asian populations. Turning to COPD, selected observational studies from Asia, Europe and the United States suggest differences in body mass index, chronic bronchitis and exacerbation history across the groups studied. These findings should not be taken as uniform characteristics of all Asian patients. Breathlessness, reduced daily activity and long-term outcomes also deserve attention, even when exacerbations are less frequent. Another major challenge is underdiagnosis. Studies from Japan, Korea and China have identified gaps in COPD diagnosis or previous spirometry use. Efforts to address these gaps must take local healthcare systems and resources into account. Japan's Health Japan 21 programme includes a national target to reduce COPD mortality. To support this goal, the Japanese Respiratory Society is pursuing COMORE-By2032, an ongoing initiative that links public awareness and earlier medical visits with spirometry, smoking cessation and continued care. Global evidence is essential, but improving COPD care also requires locally appropriate action and collaboration across the Asia-Pacific region.
  • Marc Miravitlles Speaker Spain
  • Q&A
Ballroom 4, Lower Ground Floor

21 November 2026, Saturday

Time Session
08:30
09:00
Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine
Marc Miravitlles Speaker Spain
Lalitha Pereirasamy Chairperson Malaysia
"Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterised by substantial variability in clinical presentation, underlying biological mechanisms, disease trajectory and response to treatment. This heterogeneity has challenged the traditional approach of classifying patients according to fixed clinical phenotypes and applying largely uniform treatment strategies. Increasing evidence supports a shift towards precision medicine, in which treatment decisions are guided by the identification of individual, measurable and clinically relevant treatable traits. The concept of treatable traits represents an evolution from phenotype-based classification towards a multidimensional assessment of the patient. Rather than assigning patients to mutually exclusive categories, this approach recognises that several clinically relevant traits may coexist within the same individual and may change over time. These traits can encompass pulmonary characteristics, such as airflow limitation, hyperinflation, emphysema, chronic bronchitis, bronchiectasis and chronic bronchial infection, as well as systemic and extrapulmonary features including cardiovascular disease, frailty, osteoporosis, skeletal muscle dysfunction, anxiety and depression, and physical inactivity. Importantly, treatable traits should not simply describe disease characteristics; they should identify clinically relevant abnormalities for which an effective intervention is available. This distinction is particularly relevant as therapeutic options for COPD continue to expand. Blood eosinophil counts, for example, can help identify patients who are more likely to benefit from inhaled corticosteroids and, more recently, from targeted biologic therapies. Similarly, frequent exacerbations, chronic bronchial infection, mucus hypersecretion, pulmonary hyperinflation and physical inactivity may each require different therapeutic strategies, ranging from pharmacological treatment to pulmonary rehabilitation, airway clearance, antimicrobial approaches or interventions aimed at reducing hyperinflation. The emergence of biologic therapies targeting specific inflammatory pathways represents an important step towards precision treatment in COPD. However, precision medicine should not be equated with precision pharmacotherapy. Its broader objective is to integrate clinical characteristics, biomarkers, imaging, physiological measurements, comorbidities, environmental exposures and patient-reported outcomes to construct an individualised disease profile and select interventions according to the dominant treatable traits. Future COPD management will therefore require dynamic rather than static patient characterisation. Treatable traits may evolve with disease progression, exacerbations, treatment and ageing, making repeated assessment essential. Digital health, artificial intelligence, multi-omics and increasingly accessible biomarkers may further improve phenotyping and prediction of treatment response. The transition from phenotypes to treatable traits offers an opportunity to move beyond a one-size-fits-all model of COPD care. The challenge now is to determine which traits are clinically meaningful, how they should be identified and prioritised, and whether treating them translates into better outcomes. Precision medicine in COPD should ultimately be judged not by the sophistication of patient classification, but by its capacity to deliver more effective, personalised and clinically meaningful care."
Ballroom 3, Lower Ground Floor